Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral GSK5460025 in dMMR or MSI-H Solid Tumors
NCT07213609Phase 2Recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of GSK5460025 in solid tumor, colorectal cancer (CRC) and endometrial cancer (EC) (2 arms), sponsored by GSK. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment Emergent Adverse Events and Serious Adverse Events at 36 months and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
GSK5460025
03
Conditions
solid tumorcolorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07213609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213609.